SynAct Pharma’s SEK 150 Million Preferential Rights Offering

Baker McKenzie acted as legal advisor to the Joint Global Coordinators with an international Capital Markets.

SynAct Pharma executed a rights issuance of shares with preferential rights for existing shareholders of approximately SEK 150 million (approx. 15.37 million) at a subscription price of SEK 63 per share. 

SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases.

ABG Sundal Collier and Kempen & Co are Joint Global Coordinators in connection with the preferential rights issue. 

The Baker McKenzie team consisted of Joakim Falkner (Picture) and Johanna Flink in Stockholm as well as Adam Farlow and Charles Farnsworth in London.

Involved fees earner: Joakim Falkner – Baker McKenzie; Adam Farlow – Baker McKenzie; Charles Farnsworth – Baker McKenzie; Johanna Flink – Baker McKenzie;

Law Firms: Baker McKenzie;

Clients: ABG Sundal Collier AB ; Kempen & Co;